Letter to the Editor Regarding: “Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain”

Oncology and Therapy 2026 Open access

Read full text
Authors: Kirsten JM. van Nimwegen, Mustafa Oguz, Raúl Morano, Joris Diels
DOI: 10.1007/s40487-026-00420-3
Cited by: 1
References: 9

Abstract

Letter to the Editor Regarding: "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain"

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Health Systems Economic Evaluations Quality of Life Economic and Financial Impacts of Cancer

Publication details

Journal / source
Oncology and Therapy
Publisher
Springer Science and Business Media LLC
Volume
14
Issue
1
Pages
423–427
Publication date
27 February 2026
Language
EN